RxDoctor Payments Data

Whitney Moose

Family · Statesville, NCNPI 1366892432

Payments from drug & device makers

$2,955in general payments, 2019–2025

Across 106 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$911
  • Inspire Medical Systems, Inc.$501
  • GSK$310
  • United Therapeutics Corporation$126
  • Paratek Pharmaceuticals, Inc.$125
  • Intuitive Surgical$124
  • plus $858 from 17 others

What the payments were for

  • Travel & lodging$2559%
  • Food & beverage$2,61088%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,955 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$46,658
Medicare patients
261
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$337,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter353$269,254
Breztri AerosphereBudesonide/Glycopyr/Formoterol123$97,889
Breo ElliptaFluticasone/Vilanterol94$49,713
Spiriva RespimatTiotropium Bromide82$49,443
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$38,894
Stiolto RespimatTiotropium Br/Olodaterol Hcl70$36,773
SymbicortBudesonide/Formoterol Fumarate124$34,426
EliquisApixaban34$32,033
Pirfenidone16$12,216
Combivent RespimatIpratropium/Albuterol Sulfate23$11,212
Albuterol Sulfate HfaAlbuterol Sulfate319$7,987
DuleraMometasone/Formoterol17$6,377
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$5,384
Ventolin HfaAlbuterol Sulfate83$4,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$94$434,878198 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$310$362,455524 claims
AstraZenecaBreztri Aerosphere, Symbicort$911$132,315247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.

Other family in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →